+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language
Pharmacovigilance

Pharmacovigilance

Upon the granting of a Marketing Authorization (MA) for a medicinal product, the MA Holder is required to implement a series of pharmacovigilance activities to ensure the protection of public health. The primary objective is to maintain a consistently favourable benefit-risk ratio through the identification, assessment and prevention of adverse events or any other safety issues related to the use of medicinal products.

Key obligations for the MA Holder include:

  • The establishment of an appropriately structured pharmacovigilance system;
  • The appointment of a Qualified Person Responsible for Pharmacovigilance (QPPV), responsible for managing the aforementioned system, who must be permanently and continuously available to the MA Holder.

The QPPV role is mandated by both European legislation (Directive 2001/83/EC, as amended, and Good Pharmacovigilance Practices – GVP) and UK regulations (Human Medicines Regulations). The EUQPPV and UKQPPV are responsible for the MA Holder’s pharmacovigilance system, the details of which are documented in the Pharmacovigilance System Master File (PSMF).
Furthermore, companies holding marketing authorizations in EU Member States must, where necessary, appoint a Local Responsible for Pharmacovigilance/Local Contact Point. In Italy, registration with the National Pharmacovigilance Network (RNF) of the Italian Medicines Agency (AIFA) is necessary.

Our Solutions

Di Renzo Regulatory Affairs offers a specialized pharmacovigilance unit, comprising highly qualified experts capable of fulfilling the roles of EUQPPV, UKQPPV, and Deputy. The unit can also act as a Local Responsible for Pharmacovigilance/Local Contact Point in Italy.

Leveraging its international reach and collaboration with expert consultants across various EU and non-EU countries, Di Renzo Regulatory Affairs can establish a pharmacovigilance network by integrating Local Responsible for Pharmacovigilance/Local Contact Point within the Company’s target territories. This enables the creation of a tailored pharmacovigilance network, specifically designed for the Company’s products and the markets in which they are authorized.